Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

I’m Kelly Grant, a health reporter with The Globe and Mail. Yesterday, the Canadian Medical Association Journal published the ...

UBT251 is different from Novo Nordisk’s current drugs like Ozempic and Wegovy ... fatty liver disease, chronic kidney disease and those who are overweight or obese. It is also approved for ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...